Dianthus Therapeutics, Inc. /DE/ (DNTH)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Dianthus Therapeutics, Inc. /DE/ reported revenue of $2.04M, down 67.3% from the prior year. The company ran a net loss, with a net margin of -7973.3%. It held $530.92M in total assets against $37.52M in total liabilities.
Key ratios (FY2025)
-8739.3%
Operating margin
-7973.3%
Net margin
-32.9%
Return on equity
-67.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | — | — | — | $0 | $0 | $0 | $0 |
| Operating Income | -$177.93M | -$101.86M | -$48.17M | -$29.70M | -$74.69M | -$78.70M | -$82.97M | -$59.96M | -$35.73M | -$9.27M |
| Net Income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -$71.14M | -$74.94M | -$76.77M | -$57.52M | -$35.49M | -$9.43M |
| EPS (Diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 | $-1.71 | — | — | — | — |
| Total Assets | $530.92M | $374.01M | $179.41M | $83.11M | $189.93M | $161.62M | $161.51M | $157.31M | $54.46M | — |
| Total Liabilities | $37.52M | $21.53M | $10.54M | $9.45M | $17.26M | $17.71M | $20.32M | $11.66M | $4.14M | — |
| Shareholders' Equity | $493.40M | $352.48M | $168.87M | -$44.37M | -$17.25M | $143.91M | $141.19M | $145.65M | -$42.12M | -$8.87M |
| Cash & Equivalents | $51.09M | $22.79M | $132.32M | $15.37M | $131.65M | $58.15M | $65.07M | $58.34M | $51.40M | — |
| Operating Cash Flow | -$129.06M | -$78.18M | -$36.86M | -$29.07M | -$59.53M | -$64.02M | -$57.10M | -$41.89M | -$22.26M | -$6.53M |
| Capital Expenditures | — | — | — | $314.0K | $1.26M | $400.0K | $3.06M | $7.67M | $2.20M | $139.0K |
| Shares Outstanding | 43.22M | 31.12M | 14.82M | 875.3K | 58.80M | 48.53M | 39.26M | 33.31M | 2.35M | — |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |